Further, we suggest that mGluR5 treatment might also be beneficial in “positive valence disorders” such as addiction and depression, via abnormal mGluR5 activity on brain structure and function related to the glutamatergic NMDA receptor that is functionally linked with mGluR5 and importantly involved in reward learning. Here, GRM5 is linked to depressive disorder.